| ORIGINAL ARTICLE |
|
| Year : 2014 | Volume
: 10
| Issue : 5 | Page : 42-45 |
|
|
The clinical value of Fufangkushen injection in the treatment of stomach cancer: A meta-analysis
Jin Li1, Mingdong Wu2, Qingzhong Tian1, Guangwei Xie1, Yuanchao Hu1, Qingliang Meng1, Minkang Zhang1
1 Department of Oncology Surgery, Xuzhou Central Hospital, Affiliated Hospital of Medical College of Southeast University, Xuzhou, China
2 Department of Pharmacy, Lishui People's Hospital, Lishui, China
Correspondence Address:
Minkang Zhang
Department of Oncology Surgery, Xuzhou Central Hospital, Affiliated Hospital of Medical College of Southeast University, Xuzhou - 221 009
China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.139755
|
|
|
Objective: The purpose of this meta-analysis was to evaluate the effects of Fufangkushen injection combined with chemotherapy in the treatment of stomach cancer.
Materials and Methods: The relevant clinical trials about Fufangkushen injection combined with chemotherapy in the treatment of stomach cancer were search in the data bases of Pubmed, EMBASE, Cochran and CNKI. The data related to objective response rate, Karnofsky (KPS) score and toxicity were extracted and pooled using the Stata 11.0 software. Dichotomous data was presented as risk ratio (RR) and its 95% confidence interval (95% CI).
Results: Thirteen relevant trials were included in this meta-analysis. Heterogeneity test indicated there was no statistical heterogeneity among the studies, thus the fixed effects mode was used to calculat the results. Pooled results indicated that the objective response rate (ORR) and KPS score improvement in Fufangkushen chemotherapy group was significant higher than that of control group (RR = 1.24, P < 0.05). Synthesis data also demonstrated the Fufangkushen injection can significantly decrease the risk of developing granulocytopenia in stomach cancer patients treated with chemotherapy (RR = 0.67,P < 0.05).
Conclusion: Fufangkushen injection combined with chemotherapy can increase the objective response rate, improve the quality of life and decrease the risk of developing granulocytopenia in patients with stomach cancer.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
